• Voluntarily participate in the study and signed the ICF;

• Male or female, aged 18-75 years;

• All participants to be enrolled must be diagnosed with histopathologically or cytologically confirmed, unresectable locally advanced (stage IIIB/IIIC )or recurrent metastatic NSCLC (stage IV ) and not amendable to curative surgery or radiation as assessed by investigator;

• For previously locally advanced or recurrent metastatic disease not treated with systemic antitumor therapy;

• Carring 1 of 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., exon 19 deletion or L858R) and MET positivity;

• Ability to provide at least 6 sections of tumor tissue specimens for staining and testing；

• ECOG PS score 0 or 1；

• At least one measurable lesion according to RECIST v1.1 criteria；

• Expected survival ≥ 12 weeks;

⁃ Adequate bone marrow and organ function；

⁃ Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until 6 months after the last dose, during which time the female subject is not breastfeeding and the male subject avoids sperm donation.